Key result
Laparoscopic sleeve gastrectomy effectively treated metabolic syndrome components and obesity-related comorbidities, and improved inflammatory, kidney, and liver biomarkers at 1-year follow-up.
Why the study?
To assess the efficiency of laparoscopic sleeve gastrectomy in resolving metabolic syndrome components, treating comorbidities, and influencing biochemical markers.
Does laparoscopic sleeve gastrectomy improve metabolic syndrome components and biochemical markers in patients with morbid obesity?
Cohort (n=211)
Does laparoscopic sleeve gastrectomy improve metabolic syndrome components and biochemical markers in patients with morbid obesity?
Laparoscopic sleeve gastrectomy effectively treats metabolic syndrome components and improves inflammatory, kidney, and liver biomarkers at 1-year follow-up.
Answers are grounded in this paper and cite their sources.
Metabolic surgery was associated with MS improvement in obesity; leaves open need for RCTs to guide practice.
INTRODUCTION: The worldwide outbreak of morbid obesity forced contemporary medicine to adopt a multidisciplinary approach, which led to the description of metabolic syndrome (MS): a disease with self-aggravating components and one of the most important causes of morbidity and mortality. The need for therapeutic methods provoked development of metabolic surgery, which nowadays give possibilities for safe and effective treatment of all MS aspects simultaneously and improves many obesity-related comorbidities. AIM: To assess the laparoscopic sleeve gastrectomy (LSG) procedure's efficiency in resolving MS components, treating comorbidities and to analyze the influence on certain biochemical markers in 1-year follow-up. MATERIAL AND METHODS: The retrospective cohort study of 211 patients after an LSG operation relied on statistical analysis of clinical data collected prospectively in follow-up visits. All applicable guidelines and bioethical recommendations were respected in this study. CONCLUSIONS: The LSG is an effective method of treatment in all areas of metabolic syndrome, provides a significant positive clinical outcome in obesity-related comorbidities and induces desirable changes in inflammatory, kidney and liver related biomarkers.
No takes yet. Share an insight, caveat, or question.
Wójciak et al. (2019) conducted a cohort in Metabolic syndrome and morbid obesity (n=211). Laparoscopic sleeve gastrectomy was evaluated on Resolution of metabolic syndrome components, comorbidities, and biochemical markers. Laparoscopic sleeve gastrectomy effectively treated metabolic syndrome components and obesity-related comorbidities, and improved inflammatory, kidney, and liver biomarkers at 1-year follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: